Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

The Dyslipidemia Market: Can Growth Be Sustained as Statin Patents Expire?

Published by: Decision Resources

Published: Mar. 31, 2006 - 20 Pages

Price reduced due to age.

Table of Contents


Statins and the Cardiovascular Market

Overview of Dyslipidemia

Lipoproteins in the Blood

Dyslipidemia and Cardiovascular Disease

Prevalence of Dyslipidemia

Current Treatments

Statins

Fibrates

Cholesterol Modulators

Bile Acid Sequestrants

Nicotinic Acid (Niacin)

Cholesterol Absorption Inhibitors

Combination Products

Current Market Status

United States

Europe

Japan

Key Patent Expiries

Agents in Development

PPAR Agonists

Cholesterol Modulators

CETP Inhibitors

ACAT Inhibitors

Nicotinic Acid Antagonists

Squalene Synthetase Inhibitors

Combination Products

Lp-PLA2 Inhibitor

Statins

Market Outlook

United States

Europe

Japan

Figure 1 Prevalence of Dyslipidemia in the Seven Major Markets, 2005

Table 1 Sales of Leading Agents for the Treatment of Dyslipidemia, 2005 (millions of U.S. dollars)

Figure 2 U.S. Sales of Statins and Ezetimibe-Containing Combinations, 1999-2004

Figure 3 Distribution of the European Dyslipidemia Market, 2004

Table 1 Sales of Leading Agents for the Treatment of Dyslipidemia, 2005

Table 2 Drugs in Clinical Development for the Treatment of Dyslipidemia, 2006

Table 3 Dyslipidemia Sales in the Seven Major Markets, 2004-2014

Abstract

Dyslipidemia is a key independent risk factor for cardiovascular disease (CVD); CVD is the largest therapeutic segment of the world pharmaceutical market, and treatment of dyslipidemia represents a major sector of the CVD market. This report provides an overview of the condition, its role in CVD, and its prevalence. We discuss Dyslipidemia treatments, with a focus on the statins as the dominant treatment choice worldwide. We review key patent expiries, including the imminent U.S. expiries of pravastatin (Bristol-Myers Squibb’s Pravachol) and simvastatin (Merck & Co.’s Zocor) and the expected 2011 patent expiry of the best-selling statin, atorvastatin (Pfizer’s Lipitor). In addition, we discuss emerging agents in this market, highlighting the effect generic agents may have on their adoption, or the effect these new agents may have on generics erosion of the market. Finally, we present our expectations for the market throughout our 2004-2014 forecast period.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008